You are here

Article Text

Article menu
Download PDFPDF
Economics
Rate control was more cost effective than rhythm control in persistent atrial fibrillation

https://doi.org/10.1136/ebm.10.2.59

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Hagens VE, Vermeulen KM, TenVergert EM, et al. Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation—results from the RAte Control versus Electrical cardioversion (RACE) study. Eur Heart J 2004;25:1542–9.
    OpenUrlAbstract/FREE Full Text

    
 
 Q In patients with persistent atrial fibrillation, is rate control more cost effective than rhythm control for reducing cardiovascular morbidity and mortality?

    Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★★☆ Internal medicine★★★★★★☆ Cardiology ★★★★★☆☆

    METHODS

    Embedded ImageDesign:

    cost effectiveness analysis (from a societal perspective) of a randomised controlled trial (RAte Control versus Electrical cardioversion [RACE]).

    Embedded ImageAllocation:

    concealed.*

    Embedded ImageBlinding:

    blinded (outcome assessors and monitoring committee).*

    Embedded ImageFollow up period:

    mean 2.3 years.

    Embedded ImageSetting:

    31 centres in the Netherlands.

    Embedded ImagePatients:

    522 patients who had recurrent persistent atrial fibrillation or flutter, 1–2 electrical cardioversions during the previous 2 years, and no contraindications to oral anticoagulation. Exclusion criteria: arrhythmia lasting >1 year, New York Heart Association class IV heart failure, current or previous treatment with amiodarone, or use of …

    View Full Text

    Footnotes

    • ↵* See glossary.

    • For correspondence: Dr I C Van Gelder, University Hospital Groningen, Groningen, The Netherlands. i.c.van.gelderthorax.azg.nl

    • Sources of funding: Center for Health Care Insurance; Interuniversity Cardiology Institute; 3M Pharma.

    Linked Articles

    • Glossary
      Glossary
      BMJ Publishing Group Ltd
      BMJ Evidence-Based Medicine 2005; 10 64-64 Published Online First: 30 Mar 2005. doi: 10.1136/ebm.10.2.64